A Swiss study of 73 eyes and 56 patients with age-related macular degeneration (AMD) and/or diabetic macular oedema (DMO) has demonstrated a false-positive rate of just 6.1% when using home monitoring of hyperacuity using a smartphone app.
Led by Professor Lucas Bachmann for the Medical Retina Service of the Eye Clinic of the Cantonal Hospital Lucerne, study patients receiving anti-angiogenic therapy used Oculocare’s Alleye mobile app test to track disease progression.
During the Covid-19 pandemic, home monitoring has become a vital tool for reducing face-to-face contact, but false positives can place unnecessary burden on healthcare professionals, wrote researchers in Eye, the official journal of the UK Royal College of Ophthalmologists.
